Occupational Exposure to Evrysdi

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This article responds to your request for information on Evrysdi® (risdiplam) and occupational exposure.

Download article Download

Last updated September 05, 2023


  • Based on the findings from air monitoring studies, it is highly unlikely that an individual will be exposed to Evrysdi in excess of the occupational exposure limit for risdiplam when preparing the oral solution.

    Handling Recommendations

    Healthcare professionals should exercise caution when handling Evrysdi powder for oral solution.[1]

    Avoid inhalation and avoid direct contact with skin or mucous membranes (e.g. nostrils and mouth) with the dry powder and the constituted solution.[1]

    Wear disposable gloves during the preparation and clean-up procedure. If contact occurs, wash thoroughly with soap and water; rinse eyes with water.[1]

    Occupational exposure limits

    The occupational exposure limit (OEL) is the maximum concentration of a substance in the air that a worker can be exposed to in an 8-hour workday for a 40-year working lifetime without experiencing an adverse event.[2]

    Roche OEL for Evrysdi

    The Roche OEL for Evrysdi is 2 µg/m³ as an 8-hour time weighted average.

    Evrysdi air monitoring study overview

    Roche conducted air monitoring studies to determine a healthcare professional’s potential exposure to risdiplam during the preparation of Evsrydi oral solution without using a fume hood or other type of ventilated enclosure.[3] One set of control samples was collected during typical constitutions while another set of samples was collected during two incident scenarios:

    • Dropping an open bottle from a height of 10 cm, and
      • Tipping an open bottle over onto the table.

        The results were compared with the Roche OEL for Evrysdi.

        Air monitoring strategy

        To obtain a statistically representative estimate of exposure during typical constitutions without incident, personal samples were collected during six constitutions of 15 minutes each.[3] The constitution steps followed during the air monitoring study mirror the instructions for constitution for pharmacists in a real world setting. For the scenarios where incidents occurred, the maximum personal monitoring results were collected when the bottle was dropped from a height of 10 cm. The 15 minute exposure results for a single constituton for both the control and dropping scenarios were then extrapolated to 8 hours.

        Evrysdi air monitoring study results

        The results are shown in Table 1.[3]

        Table 1. Personal monitoring results

        Constitutions without incident in 15-minute exposure results and 8-hour exposure results for Dropping bottle from height of 10cm
        Note: Experience has shown that multiple exposure measurements collected from either a single individual or from multiple individuals within an exposure group are log-normally distributed. Therefore, when averaging a lognormal distribution, the geometric mean is relevant rather than the typically used arithmetic mean. Also relevant for this study is the 95th percentile i.e., the concentration under which 95% of all concentrations will fall.

        Occupational exposure when constituting Evrysdi without incident

        For an individual performing a single constitution per day, the 8-hour level was well below the OEL for risdiplam of 2 µg/m³. It would require the same person to make 140 constitutions in one day before the 95th percentile concentration exceeds the OEL.[3]

        Occupational exposure when dropping bottle from a height of 10 cm

        For an individual experiencing a single incident of dropping an Evrysdi bottle per day, 8-hour exposure was well below the OEL for risdiplam of 2 µg/m3. It would take forty such incidents per day before the 95th percentile concentration exceeds the OEL.[3]


        1. Roche Internal Regulatory Report (Accessed on 8 August 2023).
          1. Occupational exposure limits. Available at https://echa.europa.eu/oel. Accessed on July 12, 2023.
            1. Roche Internal Technical Report (Accessed on 8 August 2023).

              Welcome to Medically

              The Roche Science Hub

              This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

              Not a healthcare professional? Browse:

              This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

              You are Leaving Medically

              By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.